Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 3205 Cyclophosphamide 3200 Carboplatin 2979 Radiotherapy 2790 Paclitaxel 2720 Gemcitabine 2573 pembrolizumab 2388 Bevacizumab 2210 Docetaxel 2200 Fluorouracil 1851 Capecitabine 1834 Oxaliplatin 1742 Dexamethasone 1606 Nivolumab 1581 Doxorubicin 1503 Rituximab 1489 Magnetic Resonance Spectroscopy 1391 Etoposide 1346 Irinotecan 1248 Leucovorin 1227 Drug Therapy 1205 Cytarabine 1131 Pemetrexed 1078 fludarabine 1065 Specimen Handling 1021 Vincristine 966 Trastuzumab 946 Cetuximab 945 Prednisone 943 Lenalidomide 938

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡